Jesse J Smith
Overview
Explore the profile of Jesse J Smith including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
3685
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yuval J, Thompson H, Verheij F, Fiasconaro M, Patil S, Widmar M, et al.
Dis Colon Rectum
. 2023 Jan;
66(10):1347-1358.
PMID: 36649145
Background: Laparoscopic resection for colon cancer has not been associated with improvements in oncological outcomes in comparison to open resection. Robotic resections are associated with increased lymph node yield and...
2.
Neil C, Seiler M, Reynolds D, Smith J, Vaillancourt F, Smith P, et al.
Trends Pharmacol Sci
. 2022 Mar;
43(5):437-454.
PMID: 35331569
The production of a mature mRNA requires coordination of multiple processing steps, which ultimately control its content, localization, and stability. These steps include some of the largest macromolecular machines in...
3.
Fedoriw A, Rajapurkar S, OBrien S, Gerhart S, Mitchell L, Adams N, et al.
Cancer Cell
. 2019 Jul;
36(1):100-114.e25.
PMID: 31257072
Type I protein arginine methyltransferases (PRMTs) catalyze asymmetric dimethylation of arginines on proteins. Type I PRMTs and their substrates have been implicated in human cancers, suggesting inhibition of type I...
4.
Thomenius M, Totman J, Harvey D, Mitchell L, Riera T, Cosmopoulos K, et al.
PLoS One
. 2018 Jun;
13(6):e0197372.
PMID: 29856759
A key challenge in the development of precision medicine is defining the phenotypic consequences of pharmacological modulation of specific target macromolecules. To address this issue, a variety of genetic, molecular...
5.
Brach D, Johnston-Blackwell D, Drew A, Lingaraj T, Motwani V, Warholic N, et al.
Mol Cancer Ther
. 2017 Aug;
16(11):2586-2597.
PMID: 28835384
The EZH2 small-molecule inhibitor tazemetostat (EPZ-6438) is currently being evaluated in phase II clinical trials for the treatment of non-Hodgkin lymphoma (NHL). We have previously shown that EZH2 inhibitors display...
6.
Campbell C, Haladyna J, Drubin D, Thomson T, Maria M, Yamauchi T, et al.
Mol Cancer Ther
. 2017 Apr;
16(8):1669-1679.
PMID: 28428443
DOT1L is a protein methyltransferase involved in the development and maintenance of -rearranged (-r) leukemia through its ectopic methylation of histones associated with well-characterized leukemic genes. Pinometostat (EPZ-5676), a selective...
7.
Chan-Penebre E, Armstrong K, Drew A, Grassian A, Feldman I, Knutson S, et al.
Mol Cancer Ther
. 2017 Mar;
16(5):850-860.
PMID: 28292935
The SWI/SNF complex is a major regulator of gene expression and is increasingly thought to play an important role in human cancer, as evidenced by the high frequency of subunit...
8.
Kawano S, Grassian A, Tsuda M, Knutson S, Warholic N, Kuznetsov G, et al.
PLoS One
. 2017 Jan;
12(1):e0170539.
PMID: 28085948
[This corrects the article DOI: 10.1371/journal.pone.0158888.].
9.
Duncan K, Rioux N, Boriack-Sjodin P, Munchhof M, Reiter L, Majer C, et al.
ACS Med Chem Lett
. 2016 Mar;
7(2):162-6.
PMID: 26985292
The recent publication of a potent and selective inhibitor of protein methyltransferase 5 (PRMT5) provides the scientific community with in vivo-active tool compound EPZ015666 (GSK3235025) to probe the underlying pharmacology...
10.
Mitchell L, Boriack-Sjodin P, Smith S, Thomenius M, Rioux N, Munchhof M, et al.
ACS Med Chem Lett
. 2016 Mar;
7(2):134-8.
PMID: 26985287
SMYD3 has been implicated in a range of cancers; however, until now no potent selective small molecule inhibitors have been available for target validation studies. A novel oxindole series of...